AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
AAPL   316.73 (-0.68%)
MSFT   181.57 (-1.06%)
FB   232.20 (-1.15%)
GOOGL   1,421.37 (+0.58%)
AMZN   2,421.86 (-0.62%)
NVDA   348.71 (-3.42%)
CGC   20.01 (+3.04%)
BABA   201.72 (+1.01%)
MU   45.80 (+1.91%)
GE   6.80 (+6.08%)
TSLA   818.87 (+0.24%)
AMD   53.19 (-3.59%)
T   30.82 (+3.15%)
ACB   15.61 (-2.50%)
GILD   73.18 (-0.22%)
DIS   120.95 (+2.48%)
NFLX   414.77 (-3.39%)
BA   144.73 (+5.24%)
Log in

NASDAQ:PGENPrecigen Stock Price, Forecast & News

$2.57
+0.09 (+3.63 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.44
Now: $2.57
$2.61
50-Day Range
$2.48
MA: $3.01
$3.87
52-Week Range
$1.26
Now: $2.57
$8.77
Volume940,800 shs
Average Volume1.25 million shs
Market Capitalization$438.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Read More
Precigen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.25 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PGEN
CUSIPN/A
Phone301-556-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.72 million
Book Value$0.44 per share

Profitability

Net Income$-322,320,000.00
Net Margins-300.01%

Miscellaneous

Employees770
Market Cap$438.59 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive PGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.

Precigen (NASDAQ:PGEN) Frequently Asked Questions

How has Precigen's stock been impacted by COVID-19 (Coronavirus)?

Precigen's stock was trading at $2.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PGEN shares have increased by 8.0% and is now trading at $2.57. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Precigen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precigen in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Precigen.

When is Precigen's next earnings date?

Precigen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Precigen.

How were Precigen's earnings last quarter?

Precigen, Inc. (NASDAQ:PGEN) issued its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.19) EPS for the quarter. The biotechnology company earned $29.84 million during the quarter. Precigen had a negative return on equity of 81.74% and a negative net margin of 300.01%. View Precigen's earnings history.

What price target have analysts set for PGEN?

3 Wall Street analysts have issued twelve-month price objectives for Precigen's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Precigen's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 172.4% from the stock's current price. View analysts' price targets for Precigen.

What are Wall Street analysts saying about Precigen stock?

Here are some recent quotes from research analysts about Precigen stock:
  • 1. According to Zacks Investment Research, "Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland. " (5/26/2020)
  • 2. Northland Securities analysts commented, "We believe the company will spin-off its assets as the company has backed away from its target cash burn goal of $70M." (8/12/2019)

Has Precigen been receiving favorable news coverage?

Media coverage about PGEN stock has trended extremely negative recently, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Precigen earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutPrecigen.

Who are some of Precigen's key competitors?

What other stocks do shareholders of Precigen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precigen investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Alibaba Group (BABA) and General Electric (GE).

Who are Precigen's key executives?

Precigen's management team includes the following people:
  • Mr. Randal J. Kirk, Exec. Chairman (Age 67, Pay $100k)
  • Dr. Helen Sabzevari MPH, Ph.D., Pres & CEO (Age 57, Pay $614.62k)
  • Mr. Rick L. Sterling, Chief Financial Officer (Age 56, Pay $597.47k)
  • Mr. Donald P. Lehr, Chief Legal Officer & Corp. Sec. (Age 45, Pay $706.23k)
  • Dr. Thomas D. Reed, Founder & Chief Science Officer (Age 54)

What is Precigen's stock symbol?

Precigen trades on the NASDAQ under the ticker symbol "PGEN."

Who are Precigen's major shareholders?

Precigen's stock is owned by a number of institutional and retail investors. Top institutional investors include Third Security LLC (48.51%), BlackRock Inc. (4.01%), State Street Corp (2.19%), Sumitomo Mitsui Trust Holdings Inc. (1.62%), Nikko Asset Management Americas Inc. (1.62%) and Nikko Asset Management Americas Inc. (1.61%). Company insiders that own Precigen stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View institutional ownership trends for Precigen.

Which major investors are selling Precigen stock?

PGEN stock was sold by a variety of institutional investors in the last quarter, including Tudor Investment Corp Et Al. Company insiders that have sold Precigen company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Rick L Sterling, Robert F Walsh III, Thomas Bostick, and Thomas D Reed. View insider buying and selling activity for Precigen.

Which major investors are buying Precigen stock?

PGEN stock was purchased by a variety of institutional investors in the last quarter, including Third Security LLC, BlackRock Inc., State Street Corp, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Geode Capital Management LLC, and First Eagle Investment Management LLC. View insider buying and selling activity for Precigen.

How do I buy shares of Precigen?

Shares of PGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precigen's stock price today?

One share of PGEN stock can currently be purchased for approximately $2.57.

How big of a company is Precigen?

Precigen has a market capitalization of $438.59 million and generates $90.72 million in revenue each year. The biotechnology company earns $-322,320,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Precigen employs 770 workers across the globe.

What is Precigen's official website?

The official website for Precigen is www.precigen.com.

How can I contact Precigen?

Precigen's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.